ASAH3L inhibitors are a class of chemical compounds that specifically inhibit the activity of the enzyme N-acylsphingosine amidohydrolase 3-like protein (ASAH3L). ASAH3L, also referred to as neutral ceramidase, is involved in the hydrolysis of ceramide into sphingosine and fatty acids within the cell. Ceramides play a crucial role in the regulation of various cellular processes, including cell signaling, apoptosis, and lipid metabolism. By inhibiting ASAH3L, these compounds alter the balance between ceramides and their downstream metabolites, which can influence intracellular signaling pathways and cellular behavior.
The molecular mechanisms of ASAH3L inhibitors involve the binding to the enzyme's active site, preventing the breakdown of ceramides. This results in the accumulation of ceramides within the cell, which may affect membrane structure, cellular stress responses, and overall lipid homeostasis. These inhibitors are often studied to understand the biological roles of ASAH3L in various cellular environments, including the metabolism of sphingolipids. The inhibition of ASAH3L can also provide insight into how ceramides and sphingosine are involved in cellular growth, differentiation, and other vital physiological functions. By targeting this specific enzyme, ASAH3L inhibitors offer researchers a tool to dissect the complex interactions between lipid metabolism and cellular function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imipramine | 50-49-7 | sc-507545 | 5 mg | $190.00 | ||
Blocks acid sphingomyelinase, possibly affecting downstream effects on ASAH3L | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Inhibits V-ATPase, which can disrupt lysosomal function, indirectly affecting ASAH3L activity | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Caspase inhibitor; may indirectly affect ASAH3L through the apoptotic pathway | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
Inhibits neutral sphingomyelinase, potentially impacting ASAH3L's role in sphingolipid metabolism | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Inhibits Ras farnesyltransferase, potentially altering ASAH3L interactions with Ras | ||||||
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $200.00 $680.00 | 18 | |
Inhibits ceramide synthase, potentially disrupting ceramide metabolism affecting ASAH3L | ||||||
Myriocin (ISP-1) | 35891-70-4 | sc-201397 | 10 mg | $150.00 | 8 | |
Inhibits serine palmitoyltransferase, potentially impacting sphingolipid synthesis and ASAH3L | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Inhibits farnesyltransferase, potentially altering protein prenylation and ASAH3L localization | ||||||
Desipramine hydrochloride | 58-28-6 | sc-200158 sc-200158A | 100 mg 1 g | $66.00 $117.00 | 6 | |
Inhibits acid sphingomyelinase, potentially affecting downstream effects on ASAH3L | ||||||